Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 5
HOS-086159 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitors Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lomitapide (HOS-086160) avanafil (HOS-086161) sildenafil (HOS-086162) vardenafil (HOS-086163) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165) flurazepam (HOS-086166) midazolam (HOS-086167) triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 08cb4669d26fd4170f47a5f99fcf18bde7e922c35f378d07e3e1c1cab8b82945 · Zeichen 6375–8447 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 37
HOS-086390 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitor Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5.).
Ritonavir medicinal product level decreased
Herbal Preparation St. John’s Wort Herbal preparations containing St John’s wort
(Hypericum perforatum) due to the risk of
decreased plasma concentrations and reduced
clinical effects of ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flurazepam (HOS-086166) midazolam (HOS-086167) triazolam (HOS-086168) lomitapide (HOS-086160) avanafil (HOS-086161) sildenafil (HOS-086162) vardenafil (HOS-086163) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 235db82cd2afd722d3066659d7d625c3a96a3162e89ca0b2b4a6f83e7ca9d95d · Zeichen 6173–8675 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 21
HOS-086319 · Präparat HOS-083284
Sedatives/hynoptics
Clorazepate, diazepam, estazolam, Ritonavir co-administration is likely to result in increased plasma concentrations of
flurazepam, oral and parenteral clorazepate, diazepam, estazolam and flurazepam and is therefore contraindicated
midazolam (see section 4.3).
Midazolam is extensively metabolised by CYP3A4. Co-administration with
ritonavir may cause a large increase in the concentration of this benzodiazepine. No
medicinal product interaction study has been performed for the co-administration of
ritonavir with benzodiazepines. Based on data for other CYP3A4 inhibitors, plasma
concentrations of midazolam are expected to be significantly higher when
midazolam is given orally. Therefore, ritonavir should not be co-administered with
orally administered midazolam (see section 4.3), whereas caution should be used
with co-administration of ritonavir and parenteral midazolam. Data from
concomitant use of parenteral midazolam with other protease inhibitors suggest a
possible 3 – 4 fold increase in midazolam plasma levels. If ritonavir is
co-administered with parenteral midazolam, it should be done in an intensive care
unit (ICU) or similar setting which ensures close clinical monitoring and appropriate
medical management in case of respiratory depression and/or prolonged sedation.
Dosage adjustment for midazolam should be considered, especially if more than a
single dose of midazolam is administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazepam (HOS-085904) estazolam (HOS-086165) flurazepam (HOS-086166) midazolam (HOS-086167) protease (HOS-085623) clorazepate (HOS-086164)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage b4a8c845ab5d7e680623aa73248b83ee123be2ef31c29b06379c9aca6376c2f2 · Zeichen 49471–51496 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 54
HOS-086482 · Präparat HOS-083284
Sedatives/hypnotics
Clorazepate, diazepam, estazolam, Ritonavir co-administration is likely to result in increased plasma concentrations of
flurazepam, oral and parenteral clorazepate, diazepam, estazolam and flurazepam and is therefore contraindicated (see
midazolam section 4.3).
Midazolam is extensively metabolised by CYP3A4. Co-administration with ritonavir
may cause a large increase in the concentration of this benzodiazepine. No medicinal
product interaction study has been performed for the co-administration of ritonavir with
benzodiazepines. Based on data for other CYP3A4 inhibitors, plasma concentrations of
midazolam are expected to be significantly higher when midazolam is given orally.
Therefore, ritonavir should not be co-administered with orally administered midazolam
(see section 4.3), whereas caution should be used with co-administration of ritonavir and
parenteral midazolam. Data from concomitant use of parenteral midazolam with other
protease inhibitors suggest a possible 3 – 4 fold increase in midazolam plasma levels. If
ritonavir is co-administered with parenteral midazolam, it should be done in an intensive
care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate
medical management in case of respiratory depression and/or prolonged sedation. Dosage
adjustment for midazolam should be considered, especially if more than a single dose of
midazolam is administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flurazepam (HOS-086166) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165) midazolam (HOS-086167) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 26dfc2e9db64eee7e9dde0c580824f02a0381c69ed172fbd97b8c76f279a1e77 · Zeichen 51537–53525 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 6
HOS-108817 · Präparat HOS-093083
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of
Inhibitors lovastatin and simvastatin; thereby,
increasing the risk of myopathy
including rhabdomyolysis (see section
4.5).
Microsomal Lomitapide Increased plasma concentrations of
triglyceride transfer lomitapide (see section 4.5).
protein (MTTP)
inhibitor
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5).
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and
syncope). See section 4.4 and section
4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally administered
midazolam, see section 4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St John’s
wort (Hypericum perforatum) due to the
risk of decreased plasma concentrations
and reduced clinical effects of lopinavir
and ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) simvastatin (HOS-086158) lomitapide (HOS-086160) avanafil (HOS-086161) sildenafil (HOS-086162) vardenafil (HOS-086163) midazolam (HOS-086167) triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c938be9b188cbabde88400ddb49de67c2831b955f638dc8fa5306b13f1652968 · Zeichen 6187–9289 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 43–44
HOS-108990 · Präparat HOS-093083
43
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally
administered midazolam, see section
4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St
John’s wort (Hypericum perforatum)
due to the risk of decreased plasma
concentrations and reduced clinical
effects of lopinavir and ritonavir (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): midazolam (HOS-086167) triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 92a02386fc1a77aef711a4b1e6d441f26b16e78482f67469b16622696dc32d8d · Zeichen 8625–9989 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 78–79
HOS-109064 · Präparat HOS-093083
78
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5)
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and syncope).
See section 4.4 and section 4.5 for
co-administration of sildenafil in patients
with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally administered
midazolam, see section 4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St John’s
wort (Hypericum perforatum) due to the
risk of decreased plasma concentrations
and reduced clinical effects of lopinavir
and ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): avanafil (HOS-086161) sildenafil (HOS-086162) vardenafil (HOS-086163) midazolam (HOS-086167) triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 5fd5fb90c510eab32eaadc8b17bd2236491bc4b4553317338a4ddfd4a5d22f67 · Zeichen 7137–9814 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 20–21
HOS-108905 · Präparat HOS-093083
20
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be
AUC: ↑ 4-fold used with co-administration of
Due to CYP3A inhibition by Kaletra and parenteral midazolam.
lopinavir/ritonavir If Kaletra is co-administered with
parenteral midazolam, it should be
done in an intensive care unit (ICU)
or similar setting which ensures
close clinical monitoring and
appropriate medical management in
case of respiratory depression
and/or prolonged sedation. Dosage
adjustment for midazolam should be
considered especially if more than a
single dose of midazolam is
administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended
(see section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, and Felodipine, Nifedipine, Clinical monitoring of therapeutic
Nicardipine Nicardipine: and adverse effects is
Concentrations may be increased recommended when these
due to CYP3A inhibition by medicines are concomitantly
lopinavir/ritonavir. administered with Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when
due to CYP3A induction by these medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): salmeterol (HOS-086285) calcium (HOS-085615) felodipine (HOS-108908) nifedipine (HOS-086289) nicardipine (HOS-090619) dexamethasone (HOS-084535) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 07de481e5f74c75a6211a29709c221ad50916e1780e215eb7341382e9a6c287a · Zeichen 41905–45409 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56–57
HOS-109016 · Präparat HOS-093083
56
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be used
AUC: ↑ 4-fold with co-administration of Kaletra and
Due to CYP3A inhibition by parenteral midazolam. If Kaletra is
lopinavir/ritonavir co-administered with parenteral
midazolam, it should be done in an
intensive care unit (ICU) or similar
setting which ensures close clinical
monitoring and appropriate medical
management in case of respiratory
depression and/or prolonged sedation.
Dosage adjustment for midazolam
should be considered especially if
more than a single dose of midazolam
is administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and sinus
tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended (see
section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, Felodipine, Nifedipine, Clinical monitoring of therapeutic
and Nicardipine Nicardipine: and adverse effects is recommended
Concentrations may be increased when these medicines are
due to CYP3A inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when these
due to CYP3A induction by medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): salmeterol (HOS-086285) calcium (HOS-085615) felodipine (HOS-108908) nifedipine (HOS-086289) nicardipine (HOS-090619) dexamethasone (HOS-084535) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage bbdb1518d507ab9bf3037f812d7ca4e3f06d2a449a3a956237657f28f1c80c69 · Zeichen 40688–43969 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 91–92
HOS-109092 · Präparat HOS-093083
91
Pimozide Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and pimozide is
of pimozide are expected to contraindicated as it may increase
increase. the risk of serious haematologic
abnormalities or other serious
adverse effects from this agent (see
section 4.3)
Quetiapine Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and quetiapine is
of quetiapine are expected to contraindicated as it may increase
increase. quetiapine-related toxicity.
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be
AUC: ↑ 4-fold used with co-administration of
Due to CYP3A inhibition by Kaletra and parenteral midazolam.
lopinavir/ritonavir If Kaletra is co-administered with
parenteral midazolam, it should be
done in an intensive care unit (ICU)
or similar setting which ensures
close clinical monitoring and
appropriate medical management in
case of respiratory depression
and/or prolonged sedation. Dosage
adjustment for midazolam should be
considered especially if more than a
single dose of midazolam is
administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and sinus
tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended (see
section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, Felodipine, Nifedipine, Clinical monitoring of therapeutic
and Nicardipine Nicardipine: and adverse effects is recommended
Concentrations may be increased when these medicines are
due to CYP3A inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when
due to CYP3A induction by these medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pimozide (HOS-085600) quetiapine (HOS-086150) midazolam (HOS-086167) salmeterol (HOS-086285) calcium (HOS-085615) felodipine (HOS-108908) nifedipine (HOS-086289) nicardipine (HOS-090619) dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 703aea6daa39d7a84dcc105bf1c63b26907c5686341c713d7b68e5df123b8727 · Zeichen 40354–44819 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24
HOS-112118 · Präparat HOS-093615
The mechanism of interaction is CYP3A4
and UGT1A1 inhibition.
Concentrations of atazanavir (when given
with ritonavir) were not significantly
affected.
Methadone, stable maintenance No significant effect on methadone No dosage adjustment is necessary
dose concentrations was observed. Given that if methadone is co-administered
(atazanavir 400 mg once daily) low dose ritonavir (100 mg twice daily) with REYATAZ.
has been shown to have no significant
effect on methadone concentrations, no
interaction is expected if methadone is co-
administered with REYATAZ, based on
these data.
PULMONARY ARTERIAL HYPERTENSION
PDE5 Inhibitors
Sildenafil Co-administration with REYATAZ may A safe and effective dose in
result in increased concentrations of the combination with REYATAZ has
PDE5 inhibitor and an increase in PDE5- not been established for sildenafil
inhibitor-associated adverse events. when used to treat pulmonary
arterial hypertension. Sildenafil,
The mechanism of interaction is CYP3A4 when used for the treatment of
inhibition by atazanavir and/or ritonavir. pulmonary arterial hypertension, is
contraindicated (see section 4.3).
SEDATIVES
Benzodiazepines
Midazolam Midazolam and triazolam are extensively Co-administration of REYATAZ
Triazolam metabolised by CYP3A4. Co- with triazolam or orally
administration with REYATAZ may cause administered midazolam is
a large increase in the concentration of contraindicated (see section 4.3),
these benzodiazepines. No drug interaction whereas caution should be used
study has been performed for the co- with co-administration of
administration of REYATAZ with REYATAZ and parenteral
benzodiazepines. Based on data for other midazolam. If REYATAZ is co-
CYP3A4 inhibitors, plasma concentrations administered with parenteral
of midazolam are expected to be midazolam, it should be done in an
significantly higher when midazolam is intensive care unit (ICU) or similar
given orally. Data from concomitant use of setting which ensures close clinical
parenteral midazolam with other protease monitoring and appropriate medical
inhibitors suggest a possible 3-4-fold management in case of respiratory
increase in midazolam plasma levels. depression and/or prolonged
sedation. Dosage adjustment for
midazolam should be considered,
especially if more than a single
dose of midazolam is administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) methadone (HOS-086198) sildenafil (HOS-086162) midazolam (HOS-086167) triazolam (HOS-086168) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage be486e27c0486d810d40c1b37da9b7f69c7a35ad1fcade19cc1e1d57a1b71724 · Zeichen 71400–75434 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 44
HOS-112157 · Präparat HOS-093615
Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ
with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a
narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride,
pimozide, quinidine, bepridil, triazolam, orally administered midazolam, lomitapide, and ergot
alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). Co-administration of
REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed-dose
combination is contraindicated because of the increase in grazoprevir and elbasvir plasma
concentrations and potential for the increase in risk of ALT elevations associated with increased
grazoprevir concentrations (see section 4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed-dose combination is contraindicated because of the potential increase in
the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma
concentrations (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bepridil (HOS-085612) triazolam (HOS-086168) midazolam (HOS-086167) lomitapide (HOS-086160) ergotamine (HOS-086154) dihydroergotamine (HOS-086152) elbasvir (HOS-108814) grazoprevir (HOS-108815) glecaprevir (HOS-086297) pibrentasvir (HOS-086298) ritonavir (HOS-084521) quetiapine (HOS-086150) lurasidone (HOS-086148) alfuzosin (HOS-086139) astemizole (HOS-085608) terfenadine (HOS-085607) cisapride (HOS-085610) pimozide (HOS-085600) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8c472f02d161fbf877b321685a02acd6721db094612098433562a9a244834b35 · Zeichen 315–1385 im Abschnitt
Gegenanzeigen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-114797 · Präparat HOS-094169
Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent
on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious
and/or life-threatening events. These active substances include antiarrhythmics (such as amiodarone,
bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as
dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such
as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics
(such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as
simvastatin and lovastatin) (see section 4.5). Also the use of the alpha-1 adrenoceptor antagonist
alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension. In addition,
co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly
dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and
metoprolol given in heart failure (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) lurasidone (HOS-086148) midazolam (HOS-086167) triazolam (HOS-086168) simvastatin (HOS-086158) lovastatin (HOS-086157) alfuzosin (HOS-086139) sildenafil (HOS-086162) flecainide (HOS-086203) propafenone (HOS-084530) metoprolol (HOS-090094) pimozide (HOS-085600) sertindole (HOS-085601) ritonavir (HOS-084521) amiodarone (HOS-085596) bepridil (HOS-085612) quinidine (HOS-085593) astemizole (HOS-085608) terfenadine (HOS-085607) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 899ebcf3829943bae5ad39416161803c04f5d7f21f78b5a86a8cc0fb492896e8 · Zeichen 519–1660 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-114802 · Präparat HOS-094169
A cocktail study was conducted in 16 healthy volunteers with twice-daily 500 mg tipranavir with
200 mg ritonavir capsule administration for 10 days to assess the net effect on the activity of hepatic
CYP 1A2 (caffeine), 2C9 (warfarin), 2D6 (dextromethorphan), both intestinal/hepatic CYP 3A4
(midazolam) and P-glycoprotein (P-gp) (digoxin). At steady state, there was a significant induction of
CYP 1A2 and a slight induction on CYP 2C9. Potent inhibition of CYP 2D6 and both hepatic and
intestinal CYP 3A4 activities were observed. P-gp activity is significantly inhibited after the first dose,
but there was a slight induction at steady state. Practical recommendations deriving from this study are
displayed below.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) caffeine (HOS-085902) warfarin (HOS-085950) dextromethorphan (HOS-109265) midazolam (HOS-086167) digoxin (HOS-086172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 2a982e5c09b0f6a668c37c0051183cda57e5ffd056709df7a6427409665511c0 · Zeichen 953–1670 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 20–21
HOS-114846 · Präparat HOS-094169
20
Antipsychotics
Pimozide Based on theoretical The concomitant use of Aptivus,
Sertindole considerations, tipranavir, co- co-administered with low dose
Quetiapine administered with low dose ritonavir, with antipsychotics
Lurasidone ritonavir, is expected to increase such as pimozide, sertindole,
No interaction study pimozide, sertindole, quetiapine quetiapine or lurasidone is
performed and lurasidone concentrations. contraindicated due to potential
serious and/or life threatening
Inhibition of CYP 3A4 by events, including coma (see
tipranavir/r section 4.3)
Sedatives/hypnotics
Midazolam 2 mg QD (iv) First-dose tipranavir/r: Concomitant use of Aptivus, co-
Midazolam Cmax ↔ administered with low dose
Midazolam AUC ↑ 5.1 fold ritonavir, and sedative/hypnotics
such as oral midazolam is contra-
Steady-state tipranavir/r: indicated (see section 4.3). If
Midazolam Cmax ↓ 13% Aptivus with ritonavir is
Midazolam AUC ↑ 181% administered with parenteral
midazolam, close clinical
Midazolam 5 mg QD (po) First-dose tipranavir/r monitoring for respiratory
Midazolam Cmax ↑ 5.0 fold depression and/or prolonged
Midazolam AUC ↑ 27 fold sedation should be instituted and
dosage adjustment should be
Steady-state tipranavir/r considered.
Midazolam Cmax ↑ 3.7 fold
Midazolam AUC ↑ 9.8 fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pimozide (HOS-085600) sertindole (HOS-085601) quetiapine (HOS-086150) ritonavir (HOS-084521) lurasidone (HOS-086148) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage c0ae36602a84de2f358261153f971ebc4b7d808de8e77b14a53412046fd6d54e · Zeichen 52998–55199 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranolazine (HOS-086141) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) methylergonovine (HOS-086155) elbasvir (HOS-108814) grazoprevir (HOS-108815) cisapride (HOS-085610) domperidone (HOS-114656) naloxegol (HOS-109428) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) sertindole (HOS-085601) triazolam (HOS-086168) midazolam (HOS-086167) sildenafil (HOS-086162) avanafil (HOS-086161) simvastatin (HOS-086158) lovastatin (HOS-086157) lomitapide (HOS-086160) ticagrelor (HOS-112065) ritonavir (HOS-084521) cobicistat (HOS-088111) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49
HOS-116497 · Präparat HOS-094447
Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) methylergonovine (HOS-086155) elbasvir (HOS-108814) quinidine (HOS-085593) ranolazine (HOS-086141) ritonavir (HOS-084521) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) grazoprevir (HOS-108815) cisapride (HOS-085610) domperidone (HOS-114656) naloxegol (HOS-109428) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) sertindole (HOS-085601) triazolam (HOS-086168) midazolam (HOS-086167) sildenafil (HOS-086162) avanafil (HOS-086161) simvastatin (HOS-086158) lovastatin (HOS-086157) lomitapide (HOS-086160) ticagrelor (HOS-112065)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 65–66
HOS-116532 · Präparat HOS-094447
65
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of
hypertension pulmonary arterial hypertension and pulmonary arterial hypertension
Sildenafil darunavir co-administered with low dose co-administered with PREZISTA
Tadalafil ritonavir may increase plasma and low dose ritonavir has not
concentrations of sildenafil or tadalafil. been established. There is an
(CYP3A inhibition) increased potential for
sildenafil-associated adverse
events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co-administration of
PREZISTA with low dose
ritonavir and sildenafil when used
for the treatment of pulmonary
arterial hypertension is
contraindicated (see section 4.3).
Co-administration of tadalafil for
the treatment of pulmonary arterial
hypertension with PREZISTA and
low dose ritonavir is not
recommended.
PROTON PUMP INHIBITORS
Omeprazole # PREZISTA co-administered with
darunavir AUC ↔
20 mg once daily #
darunavir Cmin ↔ low dose ritonavir can be
#
darunavir Cmax ↔ co-administered with proton pump
inhibitors without dose
adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when
Diazepam Co-administration with co-administering PREZISTA with
Estazolam PREZISTA/ritonavir may cause a large these sedatives/hypnotics and a
Flurazepam increase in the concentration of these lower dose of the
Midazolam (parenteral) medicines. sedatives/hypnotics should be
Zolpidem considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sildenafil (HOS-086162) tadalafil (HOS-086316) ritonavir (HOS-084521) omeprazole (HOS-085912) buspirone (HOS-086325) clorazepate (HOS-086164) diazepam (HOS-085904) estazolam (HOS-086165) flurazepam (HOS-086166) midazolam (HOS-086167) zolpidem (HOS-086327)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage d55e033062b465321f1e7d6496fca1203bde2ceee842c6b87a58cc57f689d470 · Zeichen 63956–67534 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 66
HOS-116533 · Präparat HOS-094447
If parenteral midazolam is If parenteral midazolam is
co-administered with PREZISTA co-administered with PREZISTA
co-administered with low dose ritonavir it with low dose ritonavir, it should
may cause a large increase in the be done in an intensive care unit
concentration of this benzodiazepine. (ICU) or similar setting, which
Data from concomitant use of parenteral ensures close clinical monitoring
midazolam with other protease inhibitors and appropriate medical
suggest a possible 3-4 fold increase in management in case of respiratory
midazolam plasma levels. depression and/or prolonged
sedation. Dose adjustment for
midazolam should be considered,
especially if more than a single
dose of midazolam is
administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) midazolam (HOS-086167) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 99927cb80663f1bd630af55d25edc7631d68419ed3378ccdc01c1b2eeda28a10 · Zeichen 67563–68979 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 66
HOS-116534 · Präparat HOS-094447
Midazolam (oral) PREZISTA with low dose
Triazolam ritonavir with triazolam or oral
midazolam is contraindicated (see
section 4.3).
TREATMENT FOR PREMATURE EJACULATION
Dapoxetine Not studied. Co-administration of boosted
PREZISTA with dapoxetine is
contraindicated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): midazolam (HOS-086167) triazolam (HOS-086168) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9eb1d9b5669a143cfca8162f42cd6e1f1282d6f69be48456de0fe46b1cff9165 · Zeichen 68983–69712 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.